Harmony Biosciences (HRMY) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 3[1], 1 Phase 2[2].
Trial NCT07219485[4] evaluates Pitolisant in Prader-Willi Syndrome with a target enrollment of 150 participants. Trial NCT07500090[5] evaluates HBS-301 tablet in Idiopathic Hypersomnia with a target enrollment of 248 participants. Trial NCT06366464[6] evaluates Pitolisant tablet in Prader-Willi Syndrome with a target enrollment of 134 participants.
HRMY has 3 Form 4 insider filings recorded at the SEC in the past 30 days[7].